Cardiopulmonary actions of prostaglandin 6-keto-E1 in the anesthetized dog. 1980

P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz

The cardiopulmonary actions of prostaglandin (PG) 6-keto-E1, a newly discovered metabolite of PGI2, were investigated in the intact chest dog. Injections of 6-keto-PGE1 into the superior vena cava in doses of 1-30 microgram caused dose-dependent decreases in pulmonary arterial and systemic arterial pressures. Inasmuch as cardiac output increased and left or right atrial pressure was unchanged, the decreases in pulmonary and systemic vascular resistances. Reductions in systemic arterial pressure and systemic vascular resistance were similar when 6-keto-PGE1 was injected into the superior vena cava or into the left atrium suggesting that this newly discovered substance is not inactivated in transit through the pulmonary vascular bed in the dog. Decreases in pulmonary arterial pressure and pulmonary vascular resistance were enhanced when pulmonary vascular tone was elevated by infusion of a stable prostaglandin endoperoxide analog or 15-methyl-PGF2 alpha. The present results demonstrate that 6-keto-PGE1 has significant vasodilator activity in pulmonary and systemic vascular beds in the dog and since this substance is not inactivated in the lung, it would serve as a circulating hormone in this species.

UI MeSH Term Description Entries
D008297 Male Males
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D011460 Prostaglandins F (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. PGF
D011463 Prostaglandins H A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2.
D011652 Pulmonary Circulation The circulation of the BLOOD through the LUNGS. Pulmonary Blood Flow,Respiratory Circulation,Circulation, Pulmonary,Circulation, Respiratory,Blood Flow, Pulmonary,Flow, Pulmonary Blood,Pulmonary Blood Flows
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
June 1980, The Journal of pharmacology and experimental therapeutics,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
October 1983, Prostaglandins,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
August 1979, European journal of pharmacology,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
December 1983, Thrombosis and haemostasis,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
December 1984, Prostaglandins, leukotrienes, and medicine,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
April 1984, Biochemical pharmacology,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
January 1989, Advances in prostaglandin, thromboxane, and leukotriene research,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
July 1981, The New England journal of medicine,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
May 1983, British journal of pharmacology,
P Nandiwada, and A L Hyman, and L P Feigen, and P J Kadowitz
January 1981, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Copied contents to your clipboard!